IFNA1 and chronic myelogenous leukemia, BCR-ABL1 positive: IFNα has been shown to be an important anti-viral therapy in the treatment of hepatitis B and C, HIV, herpes zoster, as well as in the management of different malignancies, including melanoma, chronic myelogenous leukemia (CML), B cell leukemia (BLL), follicular lymphoma, non-Hodgkin's lymphoma, mycosis fungoides, multiple myeloma, AIDS-related Kaposi's sarcoma, carcinoid, and also bladder, renal, epithelial ovarian, and skin cancer (24).